Blog | February 16, 2018

What Oppenheimer Is Doing To Support Healthcare Investors

Source: Life Science Leader
Rob Wright author page

By Rob Wright, Chief Editor, Life Science Leader
Follow Me On Twitter @RfwrightLSL

What Oppenheimer Is Doing To Support Healthcare Investors
Michael Margolis (L), R.Ph, head of life sciences and co-head of healthcare investment banking at Oppenheimer, and Rob Wright (R), Feb. 13, 2018.

As host of the BIO Buzz Center during the 2018 BIO CEO & Investor Conference in New York, Life Science Leader magazine conducted video interviews with a number of top industry executives, such as Michael Margolis, R.Ph, head of life sciences and co-head of healthcare investment banking at Oppenheimer, an investment firm that has been in business for more than 130 years. Prior to joining Oppenheimer, Margolis served as the head of healthcare investment banking at Roth Capital Partners. Previously, he was a managing director of healthcare investment banking at Merriman Curhan Ford, and a former SVP at Rodman & Renshaw. In addition to his extensive financial industry experience, Margolis also has extensive biopharmaceutical industry experience, having worked at both Novartis and Eli Lilly & Company. Below is my short BIO Buzz Center video interview with Margolis, who discusses what his firm is doing to support life science and healthcare investors.